{"id":"tp-47063","type":"article-newspaper","title":"Tiziana Life Sciences Shares Fall About 13% After Phase 2a Results","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/47063","datePublished":"2026-11-02T23:57:41.000Z","dateModified":"2026-11-02T23:57:41.000Z","language":"en","abstract":"The company said its intranasal foralumab study met both primary endpoints in patients with non-active secondary progressive multiple sclerosis.","section":"Business","references":[]}